

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations

All items marked with an \* are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name- **Orasis Pharmaceuticals** \* Website **www.orasis-pharma.com** \*

CEO name **Elad Kedar** \*

Select a CATEGORY: Biotech/Pharma or Medical Devices or Health IT/Digital \*

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below \*

- **Illuminating the Path; Innovations and Challenges in Eye Care**

You may delete the section instructions, leaving only the bolded bullet title

Answers below should not exceed 60 words per question:

**Executive Summary / Investment Rational** Orasis Pharmaceuticals is an ophthalmic pharmaceutical company which has developed and recently launched Qlosi™ (pilocarpine HCl ophthalmic solution) 0.4% in the US. Orasis' latest financing (Series D) included a \$78 million raise (Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc., Catalio Capital Management, Freepoint Capital Group, Visionary Ventures, Bluestem Capital, SBI (Japan) Innovation Fund, Sequoia Capital, and Maverick Ventures.)

**Core Technology/Product Profile** Qlosi™ is a novel corrective eye drop indicated for the treatment of presbyopia (128 million patients in the US alone). Qlosi's preservative-free formulation includes the lowest effective concentration of pilocarpine and a multi-faceted vehicle. Qlosi was designed to achieve a balance between efficacy, safety, and tolerability. Qlosi improves the ability to focus on near objects without negatively impacting distance.

**Business Strategy** Orasis Pharmaceuticals is currently launching Qlosi in the US marketplace. With ~50 sales representatives dedicated to educating eye care professionals, Orasis is focused on reestablishing the use of prescription drops to temporarily treat blurry near vision. Orasis is establishing a new cash-pay category by providing a flexible option for patients seeking a break from reading glasses.

**What's Next?** Orasis Pharmaceuticals is focused on a successful US launch, establishing a new category for treating presbyopia. Meanwhile, Orasis entered into a licensing agreement in Korea with Optus Pharmaceuticals for commercialization of Qlosi. Orasis is working to expand to other markets.